Long term outcome of AHSCT

A board to discuss future MS therapies in early stage (Phase I or II) trials.
Post Reply
Frank
Family Elder
Posts: 543
Joined: Wed Jan 03, 2007 3:00 pm
Location: Germany

Long term outcome of AHSCT

Post by Frank »

Its specially interesting because the the trial included SPMS patiens with active deterioration before treatment.
Medium duration of disease was 36 months (15–156), and medium attacking interval time was 6.5 months.

Does this mean the had MS for an average of 36 month (this would be a short time for a transition from RRMS to SPMS) or does the time refer to since when they were diagnosed as SPMS?

I also wonder what is meant by "attacking interval"? Do they mean relapse (inflamatory activity / GD+ MRI lesion) or something like time to increased sustained disability.

Anyway its encouraging news.

--Frank



Long term outcomes of autologous hematopoietic stem cell transplantation in progressive Multiple Sclerosis
08 December 2008

Background

Progressive multiple sclerosis (MS) is going with continuously disability and unresponsive to high dose steroid and immunomodulation. The autologous hematopoietic stem cell transplantation (ASCT) has been introduced in treatment of the forms of multiple sclerosis.

Due to hematopoitic stem cell transplantation involved two processes that are conditioning with high dose immunosuppressive agents and stem cell transfusion.

The short term outcomes (within 2 years after transplantation) do not preclude the immunosuppressant roles of conditionings, therefore the long term clinical outcomes after ASCT were evaluated for patients with progressive MS.

Methods

From Nov. 2001 to Jun. 2008, 34 patients with secondary progressive MS were treated with ASCT in our hospital. Of which, 26 patients were followed up more than 2 years till now. The median follow-up time was 40 months (3–83). There were 25 females (73.5%) and 9 males (26.5%). The median age of the patients was 36(20–51) years. Medium duration of disease was 36 months (15–156), and medium attacking interval time was 6.5 months (4–12). Peripheral blood stem cells were obtained by leukapheresis after mobilization with granulocyte colony-stimulating factor. BEAM, Tiniposide(600 mg/m2), melphalan(140mg/ m2), carmustin (300 mg/m2)and cytosine arabinoside (800 mg/m2), were administered as conditioning regimen.

Outcomes were evaluated by the expanded disability status scale (EDSS). No maintenance treatment was administered if no disease progression.

Results

No deaths occurred following the treatment. All patients were observed into two groups, active-free group and activity group. The former include neurological improvement and neurological stabilization after transplantation. The latter include activity with progression and relapse without progression after improvement.

Among 34 patients, 27 patients were in active-free group. Of twenty-one patients were with continuous neurological improvement without any active events. Median EDSS scores decreased from 6.0 (4.5–7.5) at transplantation to 2.0 (1.0–5) at last follow-up(p=0.000). Six patients remained neurological stable compared between the time of transplantation and last follow-up. There were 7 patients were in activity group. Of which, five patients had experience of neurological relapse during the follow-up period. However, the EDSS at relapse was lower than pre-transplantation, as well as the interval time between active events was longer than pre-transplantation.

The low doses steroid relieved the symptoms in clinical. It seems to back to relapse and remission phase. There are two patients experienced neurological deterioration within 7 months after transplantation and need further immnosuppression treatment. The confirmed active-free survival rate was 79.14% and progression-free survival rate was 94.12% at 83 months according to Kaplan and Meier survival curve. Median remission-lasting time reached 63 months (95%CI 52–74). It was a significant difference compared with 7 months (95%CI 6–7) of pre-transplantation (P=0.000).

We compared disease activity with attacking interval time, disease duration, patient’s age and EDSS of pre-transplantation. There is a relationship between active-free event and attacking interval time, OR=5.454, P=0.01(95% CI: 1.499 to 19.844,) and without relationship with duration of disease (OR=1.009, p=0.758), patient’s age (OR=1.136, P=0.147 and EDSS (OR=1.178, p=0.864) before transplantation.

Conclusions

ASCT with conditioning regimen of BEAM were able to improve or stabilize of neurological manifestations in most of progressive MS patients with failure of conventional therapy in long-term. The disease activitivy of post transplantation has a relationship with attacking interval time of pre-transplantation.

Juan Xu1,*, Tong Wu2, Li Su1,*, Bing Xin Ji3,* and Wu Han Hui3,*

1 Hematology, xuanwu hosipital, the Capital University of Medical Sciences, Beijing, China, 2 Beijing Daopei Hospital, Beijing, China, 3 Hematology, Xuan Wu Hospital, Capital university of medical science, Beijing

Source: Blood © 2008 by American Society of Hematology (08/12/08)[/quote]
Treatment: Gilenya since 01/2011, CCSVI both IJV ballooned 09/2010, Tysabri stopped after 24 Infusions and positive JCV antibody test, after LDN, ABX Wheldon Regime for 1 year.
Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Drug Pipeline”